Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Health Professional Information

ASCEND is a mail-based, placebo controlled, randomised trial which aims to demonstrate whether aspirin and/or omega-3 fatty acids reduce the risk of cardiovascular events in individuals with diabetes who do not already have diagnosed occlusive arterial disease, and whether such benefits outweigh any potential risks.

In order to do this reliably, over 15,000 participants with diabetes and no clinical evidence of occlusive arterial disease have been randomly allocated to receive 100mg aspirin daily or matching placebo tablets and 1g omega-3 fatty acids or matching placebo capsules for about 7.5 years. A study of this size should have good power to detect a 15% proportional reduction in the cardiovascular event rate among such individuals. In order to be cost-effective, this study is being undertaken predominantly by mail, with back-up from a 24-hour Freefone Service.

Results presented at the ESC Congress August 2018

  1. ASCEND A randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease: Jane Armitage and Louise Bowman on behalf of the ASCEND Study Collaborative Group
  2. ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes: Jane Armitage and Louise Bowman on behalf of the ASCEND Study Collaborative Group